Navigation Links
OncoPlex Diagnostics Announces the Addition of the Androgen Receptor Protein to Their Quantitative Breast Cancer Proteomic Panel
Date:8/8/2014

ROCKVILLE, Md., Aug. 8, 2014 /PRNewswire/ -- OncoPlex Diagnostics has developed a quantitative androgen receptor (AR) assay to add to their Breast Cancer Proteomic Panel.  The OncoPlex Diagnostics Breast Panel simultaneously measures multiple clinically-relevant tumor proteins using mass spectrometry to better inform the oncologist on therapy selection. The Breast Cancer Proteomic Panel with the inclusion of AR was featured in a presentation at the 13th Annual International Future of Breast Cancer Meeting in Huntington Beach, CA on July 19 by Dr. April Speed, Breast Surgical Oncologist, Atlanta, GA. Dr. Speed highlighted AR as a biomarker included in the multi-protein quantitation panel with EGFR, HER2, HER3, IGF1R, MET, PD-L1, and ROS1. In addition, chemotherapy guidance markers FR-alpha, hENT1, RRM1, SPARC, TOPO1, and TOPO2A are included from just two tissue sections. 

Approximately 75% of all breast cancer patients express AR, including 10-20% of all triple negative breast cancer (TNBC) patients.  Historically, women with TNBC have had limited options for treatment based on guideline-driven algorithms. AR positive TNBC patients represent a unique breast cancer subtype where new treatment options may be available.  Androgen receptor inhibitors that are FDA approved for prostate cancer are currently in clinical trials for breast cancer.  "Recent data are emerging to support androgen receptor as a drug target in breast cancer today," stated Dr. Speed, referring to data from Dr. Joyce O'Shaughnessy's group presented at the 2013 San Antonio Breast Cancer Symposium.

OncoPlex Diagnostics Protein Panels
OncoPlex Diagnostics targeted therapy panels provide actionable results for specific solid tumor indications from only two formalin-fixed, paraffin-embedded (FFPE) tissue slides.  The OncoPlex Diagnostics patented Liquid Tissue® process solubilizes FFPE tissue from micro-dissected tumor samples for precise protein quantitation by mass spectrometry analysis. This patented process includes the introduction of a control peptide for each target of interest, ensuring extremely high specificity and no false positives.

About OncoPlex Diagnostics
OncoPlex Diagnostics is the only CAP-accredited, CLIA-certified laboratory to solubilize tumor cell proteins from FFPE tissue and measure the unique peptides in the sample with absolute quantitation.  Genomic mutation analysis by Next Generation Sequencing can also be derived from the same sample. This innovative approach provides more than 20 actionable proteomic results and 50 gene mutation analysis from two tissue sections preserving precious biopsy material.


'/>"/>
SOURCE OncoPlex Diagnostics
Copyright©2014 PR Newswire.
All rights reserved

Related biology news :

1. 2012 Forecast for US Molecular Diagnostics Market Now Available From Global Information Inc.
2. Portable diagnostics designed to be shaken, not stirred
3. Ultrasensitive biosensor promising for medical diagnostics
4. Creating a future of personalized medicine: U-M forms joint venture for DNA diagnostics
5. New Market Forecasts Available for Critical Global Biotechnology Testing and Screening Markets: Molecular Diagnostics, Hematology, Clinical Chemistry and Nucleic Acid Testing
6. NIH-funded genetic sequencing tool speeds drug discovery, disease diagnostics
7. Shared Medical Resources, LLC files suit against Histologics, LLC, Womens Health Laboratories and Avero Diagnostics for Willful Patent Infringement
8. Modern Mobility Aids, Inc. Announces a Revised Agreement for the Acquisition of Lumigene
9. ChromaDex® Announces Financial Results for the Year Ended 2011
10. Improved Authentication and Confidentiality Protection. ICAP Patent Brokerage Announces for Auction Important Patents in Data Encryption and Document Security
11. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... The global Biometric ... USD 1.83 billion by 2024, according to a ... proliferation and increasing demand in commercial buildings, consumer ... the market growth.      (Logo: ... of advanced multimodal techniques for biometric authentication and ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ANGELES , Dec. 2, 2016 CytRx ... and development company specializing in oncology, today announced the ... noted sarcoma surgeon, industry consultant, and private healthcare investor, ... is a healthcare leader with clinical and strategic experience ... , CytRx,s Chairman and CEO. "As one of the ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... the value of DNA microarray comparative genomic hybridization (array CGH) for HER2 ... Cancer Symposium. Using molecular test results from tumors with previously documented positive, ...
(Date:12/2/2016)... ... December 01, 2016 , ... The Conference Forum has announced that the 3rd ... take place on February 1-3, 2017 at the Roosevelt Hotel in New York City. ... provides a unique 360-degree approach, which addresses the most up-to-date information regarding business aspects, ...
(Date:12/2/2016)... Washington, DC (PRWEB) , ... ... ... Technologies Consortium™ (ETC), a consortium of pharmaceutical and biotechnology companies dedicated to ... is seeking companies interested in supplying a vendor-supported, portable online UHPLC, with ...
Breaking Biology Technology: